StreetAlpha.app
Home › Stocks › PSNL

Personalis, Inc. (PSNL)

Healthcare
$14.80
▲ +0.00%
LAST CLOSE · NOV 17

Personalis provides cancer genomic testing services for physicians, drug developers, and diagnostics companies. It last closed at $14.80 on Nov 17, up 0.00% on the day. In the past 30 days there were 1 dark pool print totaling $792K, the largest $792K.

AI Auto Pilots
Is PSNL in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$80.8M
+16.9% vs a year ago
Net income
−$119.3M
−147.7% margin
EPS (diluted)
−$1.16
Free cash flow
−$107.7M
−133.3% margin
Valuation
Market cap
$1.6B
108.4M shares
P/E
–
No P/E while losing money
Price to sales
19.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$98.3M
At Sep 30
Shareholder equity
$212.7M
Shares outstanding
108.4M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $85.5M$85.5MFY2021FY2022: $65.0M$65.0MFY2022FY2023: $73.5M$73.5MFY2023FY2024: $84.6M$84.6MFY2024FY2025: $69.6M$69.6MFY2025

From PSNL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated PSNL in the past 90 days.
Average 12-month target
No price targets on PSNL in the past 90 days.
Latest rating changes
Lake StreetDowngrade
Jul 20Hold$16.25
BTIGMaintained
Jul 20Buy$16.25
NeedhamMaintained
Jul 17Buy$17
Morgan StanleyMaintained
Jul 9Hold$13
DateFirmActionRatingPrice target
Jul 20Lake StreetDowngradeHold$16.25
Jul 20BTIGMaintainedBuy$16.25
Jul 17NeedhamMaintainedBuy$17
Jul 9Morgan StanleyMaintainedHold$13
Loading…

Technical Analysis

PSNL · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, oversold

The stock is 6% below its 20 day and 8% below its 50 day average. It is 21% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 28), oversold. The nearest support is the Pivot at $14.78, and the nearest resistance the swing high (Aug 10) at $14.81.

Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityLow, 2.3%/day
Key levels
$18.8952 week high+27.6%
$15.9950 day average+8.0%
$15.7420 day average+6.4%
$15.30100 day average+3.4%
$15.04Pivot R1+1.6%
$14.81Swing high (Aug 10)+0.1%
$14.80Last close
$14.78Pivot−0.1%
$14.54Pivot S1−1.8%
$13.68Swing low (Aug 18)−7.6%
$11.63200 day average−21.4%
$4.9652 week low−66.5%
Indicators
RSI (14)27.75Oversold below 30Oversold
MACD-0.19Below its signal lineBearish
Stochastic16.9Near the bottom of its rangeOversold
ADX (14)20.5Weak trend
Williams %R-81.7Oversold below −80, overbought above −20Oversold
CCI (20)-358.2Oversold below −100, overbought above 100Oversold
Rate of change−6.0%Change over 10 sessionsBearish
ATR (14)$0.35Typical daily range, 2.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for PSNL

What happened before

See how PSNL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PSNL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PSNL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PSNL in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$792K
Largest print
$792K
Loading…

PSNL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲121 buying vs 82 selling
  • ▲Held by funds +2.2 pts
  • ▲Funds holding +35
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding196161+21.7%
In funds' top 1063+100.0%
Held by funds80.6%78.4%+2.2 pts
New / increased64 / 5742 / 69+9.0%
Reduced / sold out53 / 2933 / 22+49.1%
Put/call ratio0.020.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PSNL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PSNL is in one of them and how their past PSNL trades turned out.

PSNL in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PSNL in an article yet. Here's the latest on the wider market.

PSNL Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Jun 4
Who traded PSNL · since 2020
Latest 3 filings
$15K – $50KTraded May 19, 2020Filed Jun 4, 2020
$1K – $15KTraded Apr 22, 2020Filed May 4, 2020
$15K – $50KTraded Feb 14, 2020Filed Mar 4, 2020
PersonTypeAmountTradedFiledDelay
Brian MastR · FLSell$15K – $50KMay 19, 2020Jun 4, 202016 d
Brian MastR · FLSell$1K – $15KApr 22, 2020May 4, 202012 d
Brian MastR · FLBuy$15K – $50KFeb 14, 2020Mar 4, 202019 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Personalis

Personalis is a cancer genomics company based in Fremont, California. It offers genomic testing that helps physicians detect residual or recurring cancer, track how a tumor responds to treatment, and select therapies. It also sells testing to pharmaceutical and biotech companies for clinical trials and biomarker research, and provides sequencing services to diagnostics companies and population sequencing projects. Its customers include drugmakers, diagnostics firms, universities, government bodies, and cancer patients.

Headquarters
Fremont, CA
Founded
2011